Good MorningStocks ended the day driven by big tech and bank headlines. NVIDIA's CES showcase and RTX 60-Series debut helped the chip giant briefly push market value above $4.76 trillion before cooling back toward $4.5–$4.6 trillion, keeping AI enthusiasm at the market's center. JPMorgan reported a 9% adjusted profit rise in Q4—$13.03 billion, or $4.63 a share—though results were trimmed by a one-time 60-cent charge tied to its Apple Card acquisition and $2.2 billion added to loan-loss reserves. December inflation was mostly unchanged while core prices cooled slightly, a development markets watch closely for Fed policy signals.
Policy risk and regulation crept into market thinking. Nine central bankers voiced full solidarity with Fed Chair Powell amid President Trump's escalating confrontations with the Fed, and Wall Street executives warned that attacks on regulators and the credit card industry could unsettle markets. Microsoft's Brad Smith pressed lawmakers for Big Tech to shoulder the costs of sprawling AI data centers, signaling potential regulatory and cost pressures for cloud and chip providers. Featured: The 7 Warning Signals Flashing Red Right Now (Ad) 
|
Retail/Wholesale | | | Despite major gains by a small number of mega-cap tech firms last year, the market rewarded investors willing to take a chance on some slightly less well-known stocks in 2025. Among the best performers of the year were photonics company Lumentum Holdings Inc. (NASDAQ: LITE), which more than quadru... Read the Full Story |
|
|
Markets | | | Volatility is returning to Wall Street, signaling a potential fracture in the bull market sentiment that defined the previous year. Recent trading sessions have seen Nasdaq futures face noticeable downward pressure, a stark contrast to the smooth sailing investors grew accustomed to in 2025. The p... Read the Full Story |
|
Medical | | | In the last few months of 2025, shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) went on an undeniable hot streak. From the beginning of August 2025 to the end of the year, the stock rose 41%. Optimism surrounding Lilly’s current and developmental weight loss and diabetes t... Read the Full Story |
|
From Our Partners | | Wall Street veteran reveals #1 investment trend of 2026 (not AI)
Will you potentially make money or lose money in the U.S. stock market in 2026? According to the 50-year Wall Street legend who invented one of Wall Street's most popular buying and selling indicators – the answer has nothing to do with AI, quantum computing, or cryptos. Instead, it all comes down to the #1 stock he recommends you BUY now… | | And the #1 stock he recommends you SELL now. |
|
Finance | | | A convergence of factors has JPMorgan Chase & Company (NYSE: JPM) stock poised to rally in 2026. The stock surged in 2025 and could advance as much as 20% by year’s end. Below, we'll examine what's driving the JPM market and why the financial stock could see the $400 level this year. Ja... Read the Full Story |
|
Retail/Wholesale | | | Shares of tech giant Amazon.com Inc (NASDAQ: AMZN) surged more than 10% last week, starting what looks like what could be a decisive run toward November's all-time high. The move hasn't come out of the blue. For months now, the stock has been carving out a steady series of higher lows, quietly b... Read the Full Story |
|
From Our Partners | | While everyone panicked, these coins saw 1,100% in 2 days
Bitcoin down. Altcoins down harder. Many investors are either panic selling or frozen on the sidelines. But these two are doing something different. | | Click here to see more. |
|
Technology | | | In the middle of January 2026, the two largest forces in mobile computing effectively called a truce in the war for artificial intelligence (AI) dominance. After months of speculation and market volatility, Apple Inc. (NASDAQ: AAPL) and Alphabet Inc. (NASDAQ: GOOG) formalized a strategic partnersh... Read the Full Story |
|
Technology | | | The market reaction in the finance and fintech sectors on Jan. 12, 2026, was not a panic sell-off. It was a precise, calculated sorting event. Following the Trump administration's announcement of a proposed 10% cap on credit card interest rates, the financial sector fractured. While the headlines ... Read the Full Story |
|
Technology | | | NVIDIA (NASDAQ: NVDA) has achieved a level of dominance in the stock market that defies historical comparison. The chip giant's market capitalization briefly peaked above $4.76 trillion following its dominant presentation at CES 2026, which featured the debut of its new consumer-focused RTX 60-Ser... Read the Full Story |
|
Auto/Tires/Trucks | | | After gaining just 6% last year, consumer discretionary stocks entered 2026 looking for some relief from the fallout from tariffs, margin compression, and a weakening labor market. But for automotive stocks, the situation was a little different. According to Autoweek, U.S. auto sales were strong... Read the Full Story |
|
Markets | | | In the face of inflation, changing interest rates, and broader market instability, income-generating exchange-traded funds (ETFs) may be a strong defensive choice for investors in 2026. These funds offer the benefit of steady distributions by focusing on dividend-paying stocks, on bonds, or on oth... Read the Full Story |
|
Wednesday's Early Bird Stock Of The Day Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenb... | Should I Buy Pfizer Stock? PFE Bull and Bear Case Explained These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Pfizer was last updated on Monday, January 12, 2026 at 6:25 PM. Pfizer Bull Case - The current stock price is around $27.88, which reflects a consensus target price that suggests potential for growth.
- Pfizer Inc. has recently reported earnings that exceeded analyst expectations, indicating strong financial performance and operational efficiency.
- The company has a solid dividend yield of approximately 6.8%, providing a steady income stream for investors.
- Recent strategic investments in weight loss drugs position Pfizer Inc. to capitalize on a growing market, potentially enhancing future revenue streams.
- Analysts have given a mix of ratings, with a significant number maintaining a "Hold" or "Buy" rating, suggesting confidence in the company's stability and growth potential.
Pfizer Bear Case - Negative sentiment surrounds the stock, with predictions that other healthcare stocks may outperform Pfizer Inc., which could pressure its stock price.
- Analysts have noted a recent decline in stock value, which raises concerns about the company's growth prospects and market competitiveness.
- The company's debt-to-equity ratio of 0.62 indicates a moderate level of debt, which could pose risks if market conditions worsen.
- Despite recent earnings beats, revenue fell short of analyst estimates, suggesting potential challenges in maintaining growth momentum.
- With a high dividend payout ratio of 100%, there may be concerns about the sustainability of dividend payments in the long term, especially if earnings fluctuate.
| | View Today's Stock Pick |
|
